Research Article in Silico Identification of Potent Ppar-í Μí»¾ Agonists from Traditional Chinese Medicine: a Bioactivity Prediction, Virtual Screening, and Molecular Dynamics Study
暂无分享,去创建一个
[1] K. Aldape,et al. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. , 2014, Molecular cell.
[2] Hung-Jin Huang,et al. Traditional Chinese medicine application in HIV: an in silico study , 2014, Journal of biomolecular structure & dynamics.
[3] Shu-Yao Tsai,et al. Leptin induces cell invasion and the upregulation of matrilysin in human colon cancer cells , 2013 .
[4] F. Tsai,et al. Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells , 2013 .
[5] Yitao Ding,et al. PP2A-Mediated Anticancer Therapy , 2013, Gastroenterology research and practice.
[6] Calvin Yu-Chian Chen,et al. A possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitors , 2013, Journal of biomolecular structure & dynamics.
[7] Su-Sen Chang,et al. Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine? , 2013, Journal of biomolecular structure & dynamics.
[8] Calvin Yu-Chian Chen,et al. Investigation of silent information regulator 1 (Sirt1) agonists from Traditional Chinese Medicine , 2013, Journal of biomolecular structure & dynamics.
[9] Jing-Gung Chung,et al. Crude extract of Rheum palmatum inhibits migration and invasion of U-2 OS human osteosarcoma cells by suppression of matrix metalloproteinase-2 and -9 , 2013 .
[10] Yun-Ru Chen,et al. Down-regulation of voltage-gated Ca2+ channels in Ca2+ store-depleted rat insulinoma RINm5F cells , 2013 .
[11] F. Tsai,et al. Appearance of acanthosis nigricans may precede obesity: An involvement of the insulin/IGF receptor signaling pathway , 2013 .
[12] F. Tsai,et al. Association analysis between Tourette's syndrome and two dopamine genes (DAT1, DBH) in Taiwanese children , 2013 .
[13] J. M. Suh,et al. PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.
[14] Tatsuo Yamamoto,et al. Genetic nature and virulence of community-associated methicillin-resistant Staphylococcus aureus , 2013 .
[15] Su-Sen Chang,et al. Drug Design for Neuropathic Pain Regulation from Traditional Chinese Medicine , 2013, Scientific Reports.
[16] Chia-Ling Jao,et al. Angiotensin I-converting enzyme inhibitory peptides: Inhibition mode, bioavailability, and antihypertensive effects , 2012 .
[17] F. Menaa,et al. Therapeutic approaches to drug targets in hyperlipidemia , 2012 .
[18] Calvin Yu-Chian Chen,et al. Uroporphyrinogen Decarboxylase as a Potential Target for Specific Components of Traditional Chinese Medicine: A Virtual Screening and Molecular Dynamics Study , 2012, PloS one.
[19] Susanne Mandrup,et al. PPARs: fatty acid sensors controlling metabolism. , 2012, Seminars in cell & developmental biology.
[20] K. Su. Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications , 2012 .
[21] Toshimasa Tanaka,et al. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides. , 2012, Bioorganic & medicinal chemistry.
[22] Calvin Yu-Chian Chen,et al. Two Birds with One Stone? Possible Dual-Targeting H1N1 Inhibitors from Traditional Chinese Medicine , 2011, PLoS Comput. Biol..
[23] Hsin-Yi Chen,et al. Investigation into Potent Inflammation Inhibitors from Traditional Chinese Medicine , 2011, Chemical biology & drug design.
[24] Calvin Yu-Chian Chen,et al. Identification of Potent EGFR Inhibitors from TCM Database@Taiwan , 2011, PLoS Comput. Biol..
[25] Kai-Wei Chang,et al. In silico pharmacology suggests ginger extracts may reduce stroke risks. , 2011, Molecular bioSystems.
[26] Kuan-Chung Chen,et al. Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once? , 2011, Molecular bioSystems.
[27] VINCENT ZOETE,et al. SwissParam: A fast force field generation tool for small organic molecules , 2011, J. Comput. Chem..
[28] Chih-Jen Lin,et al. LIBSVM: A library for support vector machines , 2011, TIST.
[29] Calvin Yu-Chian Chen,et al. TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico , 2011, PloS one.
[30] S. Mandrup,et al. Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation , 2010, PPAR research.
[31] Chien-Yu Chen,et al. Insights into designing the dual-targeted HER2/HSP90 inhibitors. , 2010, Journal of molecular graphics & modelling.
[32] D. Selkoe,et al. Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin , 2010, PloS one.
[33] Hualiang Jiang,et al. 7-Chloroarctinone-b as a new selective PPARγ antagonist potently blocks adipocyte differentiation , 2009, Acta Pharmacologica Sinica.
[34] Hyunsu Bae,et al. Evidence Based Complementary and Alternative Medicine , 2008, Evidence-based complementary and alternative medicine : eCAM.
[35] M. Lindstrom,et al. T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor γ Binding Properties* , 2008, Journal of Biological Chemistry.
[36] D. van der Spoel,et al. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.
[37] A. R. Miller. Today's challenges and tomorrow's opportunities: ligands to peroxisome proliferator‐activated receptors as therapies for type 2 diabetes and the metabolic syndrome , 2006 .
[38] Béatrice Desvergne,et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.
[39] G. Barish,et al. PPARs and the complex journey to obesity , 2004, Nature Medicine.
[40] Jasmine Chen,et al. The Peroxisome Proliferator‐activated Receptors: Ligands and Activators a , 1996, Annals of the New York Academy of Sciences.
[41] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[42] J M Thornton,et al. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.
[43] Anton J. Hopfinger,et al. Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..
[44] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[45] A. Balaban. Highly discriminating distance-based topological index , 1982 .
[46] Petra Koenig,et al. Information Theoretic Indices For Characterization Of Chemical Structures , 2016 .
[47] W. W. Cheatham. Peroxisome proliferator-activated receptor translational research and clinical experience. , 2010, The American journal of clinical nutrition.
[48] S. Shyue,et al. Ligand-Activated Peroxisome Proliferator–Activated Receptor- (cid:1) Protects Against Ischemic Cerebral Infarction and Neuronal Apoptosis by 14-3-3 (cid:2) Upregulation , 2009 .
[49] C. Venkatachalam,et al. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.
[50] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[51] L. Hall,et al. Molecular connectivity in chemistry and drug research , 1976 .